pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2017-27-2-274-282pulmo-850Research ArticleОБЗОРЫREVIEWGOLD (2017): что и почему изменилось в глобальной стратегии лечения хронической обструктивной болезни легкихGOLD 2017: what change were made in global strategy of treatment of chronic obstructive pulmonary disease and why?БарабановаЕ. Н.BarabanovaE. N.

Барабанова Екатерина Николаевна – кандидат медицинских наук, менеджер по медицинским и научным коммуникациям 

121614, Москва, ул. Крылатская, 17, корп. 3

Ekaterina N. Barabanova, Candidate of Medicine, Manager on Medical and Scientific Communication 

ul. Krylatskaya 17, build. 3, Moscow, 121614

ekaterina.n.barabanova@gsk.comЗАО «ГлаксоСмитКляйн Трейдинг»РоссияGlaxoSmithKline Trading PLCRussian Federation201705072017272274282Copyright © Барабанова Е.Н., 20172017Барабанова Е.Н.Barabanova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/850

В1997 г. Международной группой экспертов в области хронической обструктивной болезни легких (ХОБЛ) принято соглашение о необходимости создания Глобальной инициативы по ХОБЛ (GOLD). Первый доклад рабочей группы GOLD, ставший основой для создания в ряде стран национальных программ диагностики и лечения ХОБЛ, опубликован в2001 г. С учетом данных, накопленных за прошедшее десятилетие, в 2011–2013 гг. проведен пересмотр глобальной стратегии, в котором при оценке прогноза и выборе терапии ХОБЛ предусмотрен персонализированный подход. В конце2016 г. опубликован очередной крупный пересмотр доклада GOLD. Изменена схема категоризации пациентов ABCD, а степень ограничения воздушного потока по спирометрической классификации GOLD исключена из алгоритма выбора медикаментозной терапии. Подчеркнуто влияние правильной техники ингаляции на контроль над симптомами ХОБЛ и важность ее регулярной оценки. Добавлены новые данные по использованию комбинаций длительно действующих β2-агонистов и длительно действующих антихолинергических препаратов, а также тройной терапии. Приведена классификация обострений ХОБЛ по степени тяжести, отмечено влияние сопутствующих заболеваний на течение обострения. Расширен раздел, относящийся к пульмонологической реабилитации.

In 1997, the International Expert group on chronic obstructive pulmonary disease (COPD) has come to decision to initiate the Global Initiative for COPD (GOLD). The first GOLD report was published in 2001 and provided the basis for many national programs for COPD diagnosis and management. Research data accumulated in the next decade allowed to perform complete revision of global strategy in 2011 (updated 2013), considering personalized approach to prognosis and treatment selection in an individual patient. At the end of2016, anew comprehensive reassessment of GOLD report was released. The ABCD assessment tool has been refined; the role of spirometry in COPD management has been updated. Regular assessment of inhaler technique to improve the disease control has been emphasized. New data on therapy with long-acting β2-agonists/long acting anticholinergic combinations and «triple therapy» have been added. Classification of severity of COPD exacerbations was provided and impact of concomitant diseases was stressed. The section on pulmonary rehabilitation has been amplified.

хроническая обструктивная болезнь легкихГлобальная инициатива по хронической обструктивной болезни легкихспирометрияфармакотерапияchronic obstructive pulmonary diseaseGlobal Initiative for chronic obstructive pulmonary diseasespirometrypharmacotherapyЗАО «ГлаксоСмитКляйн Трейдинг»GlaxoSmithKline PLCReferencesLange P., Celli B., Agusti A. et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 2015; 373 (2): 111–122. DOI: 10.1056/NEJMoa1411532.Lange P., Celli B., Agusti A. et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N. Engl. J. Med. 2015; 373 (2): 111–122. DOI: 10.1056/NEJMoa1411532.Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of normal spirometry in an aging population. Am. J. Respir. Crit. Care Med. 2015; 192 (7): 817–825. DOI: 10.1164/rccm.201503-0463OC.Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of normal spirometry in an aging population. Am. J. Respir. Crit. Care Med. 2015; 192 (7): 817–825. DOI: 10.1164/rccm.201503-0463OC.Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of spirometric impairment in an aging population. Am. J. Respir. Crit. Care Med. 2016; 193 (7): 727–735. DOI: 10.1164/rccm.201508-1603OC.Vas Fragoso C.A., McAvay G., Van Ness P.H. et al. Phenotype of spirometric impairment in an aging population. Am. J. Respir. Crit. Care Med. 2016; 193 (7): 727–735. DOI: 10.1164/rccm.201508-1603OC.Lee P.N., Fariss M.W. A systematic review of possible serious adverse effects of nicotine replacement therapy. Arch. Toxicol. 2017; 91 (4): 1565–1594. DOI: 10.1007/s00204-016-1856-y.Lee P.N., Fariss M.W. A systematic review of possible serious adverse effects of nicotine replacement therapy. Arch. Toxicol. 2017; 91 (4): 1565–1594. DOI: 10.1007/s00204-016-1856-y.McNeill A., Brose L.S., Calder R.I. et al. E-cigarettes: an evidence update. A report commissioned by Public Health England: Public Health England, 2015. Available at: https:// www.gov.uk/government/uploads/system/uploads/attach-ment-data/file/457102/Ecigarettes-an-evidence-update-A-report-commissioned-by-Public-Health-England-FINAL.pdfMcNeill A., Brose L.S., Calder R.I. et al. E-cigarettes: an evidence update. A report commissioned by Public Health England: Public Health England, 2015. Available at: https:// www.gov.uk/government/uploads/system/uploads/attach-ment-data/file/457102/Ecigarettes-an-evidence-update-A-report-commissioned-by-Public-Health-England-FINAL.pdfMcRobbie H., Bullen C., Hartmann-Boyce J., Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst. Rev. 2014; (12): CD010216. DOI: 10.1002/14651858.CD010216.pub2.McRobbie H., Bullen C., Hartmann-Boyce J., Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst. Rev. 2014; (12): CD010216. DOI: 10.1002/14651858.CD010216.pub2.Kalkhoran S., Glantz S.A. E-cigarettes and smoking cessation – Author’s reply. Lancet Respir. Med. 2016; 4 (6): e26–27. DOI: 10.1016/S2213-2600(16)30025-X.Kalkhoran S., Glantz S.A. E-cigarettes and smoking cessation – Author’s reply. Lancet Respir. Med. 2016; 4 (6): e26–27. DOI: 10.1016/S2213-2600(16)30025-X.Malas M., van der Tempel J., Schwartz R. et al. Electronic cigarettes for smoking cessation: A systematic review. Nicotine Tob. Res. 2016; 18 (10): 1926–1936. DOI: 10.1093/ntr/ntw119.Malas M., van der Tempel J., Schwartz R. et al. Electronic cigarettes for smoking cessation: A systematic review. Nicotine Tob. Res. 2016; 18 (10): 1926–1936. DOI: 10.1093/ntr/ntw119.Souza M.L., Meneghini A.C., Ferraz E. et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J. Braz. Pneumol. 2009; 35 (9): 824–831.Souza M.L., Meneghini A.C., Ferraz E. et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J. Braz. Pneumol. 2009; 35 (9): 824–831.Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938. DOI: 10.1016/j.rmed.2011.01.005.Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105 (6): 930–938. DOI: 10.1016/j.rmed.2011.01.005.Sanchis J., Gich I., Pedersen S. Systematic review of errors in inhaler use: Has patient technique improved over time? Chest. 2016; 150 (2):394–406. DOI: 10.1016/j.chest.2016.03.041.Sanchis J., Gich I., Pedersen S. Systematic review of errors in inhaler use: Has patient technique improved over time? Chest. 2016; 150 (2):394–406. DOI: 10.1016/j.chest.2016.03.041.Sulaiman I., Cushen B., Greene G. et al. Objective assessment of adherence to inhalers by COPD patients. Am. J. Respir. Care Med. 2017; 195 (10): 1333–1343. DOI: 10.1164/rccm.201604-0733OC.Sulaiman I., Cushen B., Greene G. et al. Objective assessment of adherence to inhalers by COPD patients. Am. J. Respir. Care Med. 2017; 195 (10): 1333–1343. DOI: 10.1164/rccm.201604-0733OC.Rootmensen G.N., van Keimpena A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped method. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328. DOI: 10.1089/jamp.2009.0785.Rootmensen G.N., van Keimpena A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped method. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23 (5): 323–328. DOI: 10.1089/jamp.2009.0785.Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, doubleblind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, doubleblind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.Wedzicha J.A., Banerji D., Chapman K. et al. Indacaterolglycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Wedzicha J.A., Banerji D., Chapman K. et al. Indacaterolglycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.Brusselle G., Price D., Gruffydd-Jones K. et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2207–2217. DOI: 10.2147/COPD.S91694.Brusselle G., Price D., Gruffydd-Jones K. et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2207–2217. DOI: 10.2147/COPD.S91694.Singh D., Brooks J., Hagan G. et al. Superiority of “triple” therapy with salmeterol-fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63 (7): 592–598. DOI: 10.1136/thx.2007.087213.Singh D., Brooks J., Hagan G. et al. Superiority of “triple” therapy with salmeterol-fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63 (7): 592–598. DOI: 10.1136/thx.2007.087213.Frith P.A., Thompson P.J., Ratnavadivel R. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD – a randomized controlles trial. Thorax. 2015; 70 (6): 519–527. DOI: 10.1136/thoraxjnl2014-206670.Frith P.A., Thompson P.J., Ratnavadivel R. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD – a randomized controlles trial. Thorax. 2015; 70 (6): 519–527. DOI: 10.1136/thoraxjnl2014-206670.Siler T.M., Kerwin E., Singletary K. et al. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD. 2016; 13 (1): 1–10. DOI: 10.3109/15412555.2015.1034256.Siler T.M., Kerwin E., Singletary K. et al. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD. 2016; 13 (1): 1–10. DOI: 10.3109/15412555.2015.1034256.Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus ling-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI: 10.1016/S0140-6736(16)31354-X.Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus ling-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI: 10.1016/S0140-6736(16)31354-X.McCarthy B., Casey D., Devane D. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; (2): CD003793. DOI: 10.1002/14651858.CD003793.pub3.McCarthy B., Casey D., Devane D. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; (2): CD003793. DOI: 10.1002/14651858.CD003793.pub3.Galli J.A., Krahnke J.S., James Mamary A. et al. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir. Med. 2014; 108 (5): 722–728. DOI: 10.1016/j.rmed.2014.03.006.Galli J.A., Krahnke J.S., James Mamary A. et al. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir. Med. 2014; 108 (5): 722–728. DOI: 10.1016/j.rmed.2014.03.006.Coughlin S., Liang W.E., Parthasarathy S. Retrospective assessment of home ventilation to reduce rehospitalization in chronic obstructive pulmonary disease. J. Clin. Sleep Med. 2015; 11 (6): 663–670. DOI: 10.5664/jcsm.4780.Coughlin S., Liang W.E., Parthasarathy S. Retrospective assessment of home ventilation to reduce rehospitalization in chronic obstructive pulmonary disease. J. Clin. Sleep Med. 2015; 11 (6): 663–670. DOI: 10.5664/jcsm.4780.Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with in chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182 (3): 325–331. DOI: 10.1164/rccm.200912-1869OC.Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with in chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182 (3): 325–331. DOI: 10.1164/rccm.200912-1869OC.Gavish R., Levy A., Dekel O.K. et al. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest. 2015; 148 (2): 375–381. DOI: 10.1378/chest.14-1453.Gavish R., Levy A., Dekel O.K. et al. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest. 2015; 148 (2): 375–381. DOI: 10.1378/chest.14-1453.Masa J.F., Utrabo I., Gomez de Terreros J. et al. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units: precision medicine in intermediate care units. BMC Pulm. Med. 2016; 16 (1): 97. DOI: 10.1186/s12890-016-0262-9.Masa J.F., Utrabo I., Gomez de Terreros J. et al. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units: precision medicine in intermediate care units. BMC Pulm. Med. 2016; 16 (1): 97. DOI: 10.1186/s12890-016-0262-9.Houben-Wilke S., Jorres R.A., Bals R. et al. Peripheral artery disease and its clinical relevance in patients with COPD in the COSYCONET study. Am. J. Respir. Crit. Care Med. 2017; 195 (2): 189–197. DOI: 10.1164/rccm.2016020354OC.Houben-Wilke S., Jorres R.A., Bals R. et al. Peripheral artery disease and its clinical relevance in patients with COPD in the COSYCONET study. Am. J. Respir. Crit. Care Med. 2017; 195 (2): 189–197. DOI: 10.1164/rccm.2016020354OC.Bhatt S.P., Dransfield M.T. Chronic obstructive pulmonary disease and cardiovascular disease. Transl. Res. 2013; 162 (4): 237–251. DOI: 10.1016/j.trsl.2013.05.001.Bhatt S.P., Dransfield M.T. Chronic obstructive pulmonary disease and cardiovascular disease. Transl. Res. 2013; 162 (4): 237–251. DOI: 10.1016/j.trsl.2013.05.001.Jaramillo J.D., Wilson C., Stinson D.S. et al. Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk. Ann. Am. Thorac. Soc. 2015; 12 (5): 648–656. DOI: 10.1513/AnnalsATS.201412-591OC.Jaramillo J.D., Wilson C., Stinson D.S. et al. Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk. Ann. Am. Thorac. Soc. 2015; 12 (5): 648–656. DOI: 10.1513/AnnalsATS.201412-591OC.de Torres J.P., Wilson D.O., Sanchez-Salcedo P. et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am. J. Respir. Crit. Care Med. 2015; 191 (3): 285–291. DOI: 10.1164/rccm.2014071210OC.de Torres J.P., Wilson D.O., Sanchez-Salcedo P. et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am. J. Respir. Crit. Care Med. 2015; 191 (3): 285–291. DOI: 10.1164/rccm.2014071210OC.Sasaki T., Nakayama K., Yasuda H. et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patient. J. Am. Geriatr. Soc. 2009; 57 (8): 1453–1457.Sasaki T., Nakayama K., Yasuda H. et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patient. J. Am. Geriatr. Soc. 2009; 57 (8): 1453–1457.

The authors declare that there are no conflicts of interest present.